Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY22 Earnings Presentation
34 slides from Morepen Laboratories's earnings presentation, Nov 11, 2021
Slide 1: Stock exchange cover letter for investor presentation
'Ii ·** * - •• Date: 11/11/2021 iS To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Sandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Sandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 00 I Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors Presentation (Q2'
Slide 2: Q2'FY22 Earnings Presentation - November 2021
MOREPEN LABORATORIES LIMTED Q2'FY22 earnings Presentation - November 2021
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied
Slide 4: Quarterly Highlights
CONSOLIDATED Q2'FY22 performance QUARTERLY HIGHLIGHTS Rs. in crores Rs. in crores Net Revenue EBItdA 340.13 398.17 35.49 44.88 Profit before Tax 27.51 46.86 Profit after Tax EPS (3M) 27.17 37.36 Rs. 0.60 Rs. 0.83 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 JlOREPEN
Slide 5: Consolidated Quarterly Performance
CONSOLIDATED quarterly performance
Slide 6: Revenue Growth
CONSOLIDATED REVENUE GROWTH Rs. in crores 1,250 1200 1,000 AJ1% 400 750 863 398.17 772 786 300 340.13 610 500 200 250 100 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Q2'FY21 Q2'FY22 Annual performance Q2'FY22 performance JlOREPEN
Slide 7: Business Segments
CONSOLIDATED BUSINESS SEGMENTS 1\\0REPEtt API BUSINESS MEDICA CAL DEVICES C FORM R ULAT RM A IONS AT OTC OT TC ((SUBS B BSIDIA IIA A AR R RY Y Y))
Slide 8: Segments Wise Growth
CONSOLIDATED SEGMENTS WISE GROWTH API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC A % 250 150 50 30 200 122.59 28.18 201.00 40 44.98 184.62 100 150 20 23.07 30 35.17 100 90.36 50 20 10 50 10 0 0 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 0 0 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22
Slide 9: Segment Wise Breakup
STANDALONE SEGMENT WISE BREAKUP Formulations share Q2'Fy21 q2'FY22 12.2% API 5.00% 59.5% 54.5% API Diagnostic Devices 54.5% 33.3% Diagnostics 4.20% f 29.1% 33.3% revenue split Q1'FY'22 formulations 0.90% f 11.3% 12.2%
Slide 10: API Business
API BUSINESS leadership through quality
Slide 11: API Revenue
api business API REVENUE Rs. in crores 750 683 A 500 250 474 413 200 391 201.00 339 184.62 250 150 100 50 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Q2'FY21 Q2'FY22 Annual performance Q2'FY22 performance
Slide 12: Key API Products
api business KEY API PRODUCTS A ORV AT RVA RV VAS AST TA A AT TIN MONTELUKA K ST KA ^46% ^28% NEW MOLECULES LORATADINE ^99% -26%
Slide 13: POC Medical Devices
------- ~ . -- .) ) - ------ --- - ---..... / r I I I I I I I I I I POC MEDICAL DEVICES I + I market leadership I )
Slide 14: POC Revenue
POC medical devices POC REVENUE Rs. in crores 300 287 A 257 125 200 122.59 100 168 140 90.36 75 100 103 50 25 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Q2'FY21 Q2'FY22 Annual performance Q2'FY22 performance
Slide 15: Growth Drivers
poc medical devices GROWTH DRIVERS ) - ^45% ^44% gluco meters BP Monitors
Slide 16: Gluco Meter Revenue
POC medical devices GLUCO METER REVENUE Rs. in crores 200 180 A 170 150 100 120 84.72 100 93 75 65 50 50 58.27 0 25 FY'18 FY'19 FY'20 FY'21 H1'22 0 Annual performance Q2'FY21 Q2'FY22 Q2'FY22 performance
Slide 17: Gluco Meter Installed
POC medical devices GLUCO METER INSTALLED 2 1.69 1.5 1 0.98 1.11 6.15 MILLION 785 MILLION meters installed strips sold so far 0.74 0.5 0.62 q2'Fy21 0.49 MILLION q2'Fy22 90 MILLION 0 FY'18 FY'19 FY'20 FY'21 H1'22 million meter installed
Slide 18: BP Monitor Revenue
POC medical devices BP MONITOR REVENUE Rs. in crores 75 63 A 50 49 30 28.87 20 25 29 27 20.03 22 10 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Q2'FY21 Q2'FY22 Annual performance Q2'FY22 performance
Slide 19: Increasing Reach
POC medical devices INCREASING REACH '1,,t:: "•,✓• ..t'(t,: •,,. '• s" ••.,,.,., ,,.o,.,.,., ••r, ., ,,.,.• "'"•,.,, , .. .. .. .,.., , ,. Gluco and BP monitor ~ ... ·, ,., with boman irani Gluco and BP monitor with Javed akhtar pregnancy kit with kareena kapoor
Slide 20: Formulations
FORMULATIONS brandeD formulations in india
Slide 21: Formulations Revenue
FORMULATIONS FORMULATIONS REVENUE Rs. in crores 200 A 150 153 138 50 131 100 111 44.97 40 89 30 35.17 50 20 10 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Q2'FY21 Q2'FY22 Annual performance Q2'FY22 performance
Slide 22: Growth Drivers
FORMULATIONS GROWTH DRIVERS ^61% ^41% antibiotics generics ^5% ^169% gastro others
Slide 23: OTC & Nutrition
Dr. Morepen® OTC & NUTRITION
Slide 24: Gross Revenue
GROSS REVENUE Rs. in crores 100 75 86 A 65 30 50 54 52 28.18 49 20 23.08 25 10 0 FY'18 FY'19 FY'20 FY'21 H1'22 0 Annual performance Q2'FY21 Q2'FY22 Q2'FY22 performance*
Slide 25: Growth Drivers
GROWTH DRIVERS ^27% ^51% OTC products grooming ^243% -24% online range health care
Slide 26: Business Segments
BUSINESS SEGMENTS Healthcare on line sales 21.1% OTC 12% 25% Online 50.4% 12.3% Grooming GUBB 16.2% OTC grooming business segments q2'FY22
Slide 27: New Online Launches
en® NEW ONLINE LAUNCHES Iii ~ orepen 9£4Ul1FIA.S111~v. HMIHl'OO\.&.MIIHNOHR i!l ~ ~ orepen t. PCOS POWDER ~ fCIIIOCJlltlCl,i,u.~·lfflllC'IQ,I - multi-vitamins pcos powder collagen muscle food sexual wellness iron & ZInc probiotics Garcinia ...... ... .. ~ orap,e-n °'·"'°'cpen KRIL LI Q" • 1Q_ o,u.o"
Slide 28: Brand Portfolio
BRAND PORTFOLIO an established national household brand with extensive reach and trust Rs. in crores 500 400 425 A 371 347 300 388 OTC 200 Healthcare 13.4% 192.24 263 20.4% 200 150 146.84 100 100 0 50 FY'18 FY'19 FY'20 FY'21 H1'22 Devices 0 Annual performance 66.2% Q2'FY21 Q2'FY22 H1'Fy22 Q2'FY22 pe
Slide 29: R&D Spend
consolidated R&D SPEND increasing investment in R&D Rs. in crores Devices 5.8% A 8 ANDA API 40.8% 6 53.4% 6.06 4 4.25 2 h1'FY22 0 segment wise spend H1'FY21 H1'FY22 H1'FY22 SPEND 1lOREPEN
Slide 30: Financial Highlights & Ratios
FINANCIAL highlights & ratios
Slide 31: Revenue Highlights
CONSOLIDATED REVENUE HIGHLIGHTS Net Revenue Expenditure ebitda interest cash profit 400 400 50 0.75 60 398.17 * 353.29 40 44.88 0.66 300 343.13 300 54.00 304.64 0.5 40 30 35.49 200 200 20 35.20 0.25 20 100 100 0.29 10 0 0 0 0 0 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21
Slide 32: Profitability Ratios
CONSOLIDATED PROFITABILITY RATIOS Q2' FY'21 q2'FY22 change EBIDTA 0.84% f 10.43% 11.28% profit before tax 3.68% f 8.09% 11.77% profit after tax 1.39% f 7.99% 9.38%
Slide 33: Profitability Highlights
CONSOLIDATED PROFITABILITY HIGHLIGHTS PROFIT BEFORE TAX PROVISION FOR TAX PROFIT AFTER TAX EPS(RS.) AJ8% AJ8% 50 10 40 1 40 46.86 9.50 30 37.36 7.5 0.75 0.83 30 20 27.17 5 0.5 0.60 20 27.52 2.5 10 0.25 10 0.35 0 0 0 0 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 Q2'FY21 Q2'FY22 *Diluted EPS- Rs.0
Slide 34: Take Care - Thank You
Take Care thank you